Peter G Gibson1, Heather Powell, Francine M Ducharme. 1. Department of Respiratory and Sleep Medicine, Hunter Medical Research Institute, John Hunter Hospital, University of Newcastle, New Lambton, Australia. Peter.Gibson@hnehealth.nsw.gov.au <Peter.Gibson@hnehealth.nsw.gov.au>
Abstract
BACKGROUND: Combination therapy with long-acting beta-agonists (LABAs)/inhaled corticosteroids (ICSs) has become established as effective maintenance treatment for asthma. OBJECTIVE: To compare and contrast the efficacy and safety of LABAs/ICSs against different maintenance ICS strategies in adults with asthma. METHODS: Cochrane systematic reviews of randomized controlled trials (to April 2004) were identified that compared the addition of LABA to ICS against 3 inhaled corticosteroid strategies: (1) a similar dose (n = 4312 subjects), (2) a higher dose (n = 4951), and (3) a similar dose in steroid-naive subjects (n = 968). The outcomes evaluated were asthma exacerbations, asthma control, and adverse effects. Pediatric studies were excluded. RESULTS: The addition of LABA to ICSs significantly reduced the risk of exacerbations compared with a similar ICS dose, number needed to treat = 18. The effects of LABA/ICSs on exacerbations compared with the other maintenance inhaled corticosteroid strategies were not statistically significant. LABA added to inhaled corticosteroids led to significant improvements in asthma control compared with all 3 maintenance ICS strategies. There was an increased risk of tremor with LABA/ICSs that reached significance for initial therapy, number needed to harm = 21, and compared with higher ICS doses, number needed to harm = 74. CONCLUSION: Maintenance asthma therapy with LABA/ICSs has differential effects on asthma control and asthma exacerbations. CLINICAL IMPLICATIONS: The greatest benefit and least harm of LABAs comes when they are added to a similar ICS dose in adults with symptomatic asthma.
BACKGROUND: Combination therapy with long-acting beta-agonists (LABAs)/inhaled corticosteroids (ICSs) has become established as effective maintenance treatment for asthma. OBJECTIVE: To compare and contrast the efficacy and safety of LABAs/ICSs against different maintenance ICS strategies in adults with asthma. METHODS: Cochrane systematic reviews of randomized controlled trials (to April 2004) were identified that compared the addition of LABA to ICS against 3 inhaled corticosteroid strategies: (1) a similar dose (n = 4312 subjects), (2) a higher dose (n = 4951), and (3) a similar dose in steroid-naive subjects (n = 968). The outcomes evaluated were asthma exacerbations, asthma control, and adverse effects. Pediatric studies were excluded. RESULTS: The addition of LABA to ICSs significantly reduced the risk of exacerbations compared with a similar ICS dose, number needed to treat = 18. The effects of LABA/ICSs on exacerbations compared with the other maintenance inhaled corticosteroid strategies were not statistically significant. LABA added to inhaled corticosteroids led to significant improvements in asthma control compared with all 3 maintenance ICS strategies. There was an increased risk of tremor with LABA/ICSs that reached significance for initial therapy, number needed to harm = 21, and compared with higher ICS doses, number needed to harm = 74. CONCLUSION: Maintenance asthma therapy with LABA/ICSs has differential effects on asthma control and asthma exacerbations. CLINICAL IMPLICATIONS: The greatest benefit and least harm of LABAs comes when they are added to a similar ICS dose in adults with symptomatic asthma.
Authors: Stephen P Peters; Susan J Kunselman; Nikolina Icitovic; Wendy C Moore; Rodolfo Pascual; Bill T Ameredes; Homer A Boushey; William J Calhoun; Mario Castro; Reuben M Cherniack; Timothy Craig; Loren Denlinger; Linda L Engle; Emily A DiMango; John V Fahy; Elliot Israel; Nizar Jarjour; Shamsah D Kazani; Monica Kraft; Stephen C Lazarus; Robert F Lemanske; Njira Lugogo; Richard J Martin; Deborah A Meyers; Joe Ramsdell; Christine A Sorkness; E Rand Sutherland; Stanley J Szefler; Stephen I Wasserman; Michael J Walter; Michael E Wechsler; Vernon M Chinchilli; Eugene R Bleecker Journal: N Engl J Med Date: 2010-09-19 Impact factor: 91.245
Authors: Lesly-Anne Samedy-Bates; Sam S Oh; Thomas J Nuckton; Jennifer R Elhawary; Marquitta White; Tyronda Elliot; Andy M Zeiger; Celeste Eng; Sandra Salazar; Michael A LeNoir; Kelley Meade; Harold J Farber; Denise Serebrisky; Emerita Brigino-Buenaventura; William Rodriguez-Cintron; Kirsten Bibbins-Domingo; Rajesh Kumar; Shannon Thyne; Luisa N Borrell; José R Rodriguez-Santana; Maria Pino-Yanes; Esteban G Burchard Journal: Clin Pharmacol Ther Date: 2019-07-23 Impact factor: 6.875
Authors: Robert W Dal Negro; Luis Borderias; Qiaoyi Zhang; Tao Fan; Vasilisa Sazonov; Magda Guilera; Stephanie D Taylor Journal: BMC Pulm Med Date: 2009-03-30 Impact factor: 3.317